UroGen Pharma is trading at $45.54, up 4.96%, with healthcare up 1.26%, the clearest available explanation for the move.
- Announced September investor-conference appearances, including a September 9 Wells Fargo healthcare presentation.
- No new earnings, regulatory decision, financing, or major operating announcement was identified for September 2, 2026; the latest substantive releases concern the August 20 IntraGel collaboration and August 17 UGN-103 NDA submission.